

PATIENT INFORMATION

Patient Name: _____ DOB: _____ Phone: _____ Sex: M F Ht: _____ Wt: _____ lbs kg
 Primary Language: _____ Allergies: _____
 Patient Preferred Location: _____

DIAGNOSIS & CLINICAL INFORMATION

<ICD 10 CODE REQUIRED>

ICD 10 Code

G70.00 Generalized Myasthenia Gravis, w/o Acute Exacerbation
 G70.01 Generalized Myasthenia Gravis, w/ Acute Exacerbation
 Other: _____

Prescribing Information

Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established.

REQUIRED: Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. Some payors require MGFA Clinical Classification of II, III, or IV as well as MG-ADL total score ≥ 5 at initiation of therapy.
LAB RESULTS: Positive serologic test for anti-AChR antibodies.

PRESCRIPTION

Pre-Medications

Cetirizine: 10 mg PO
 Diphenhydramine: 25 mg PO
 Diphenhydramine: 25 mg IVP
 Methylprednisolone: 125 mg SIVP
 Other: _____

Vyvgart (efgartigimod alfa-fcab)

Dilute in 0.9% Sodium Chloride for a total volume of 125 mL and infuse using 0.2-micron filter

Dose:

IV: (wt < 120 kg) Infuse 10 mg/kg over 1 hour every week for 4 weeks
 IV: (wt \geq 120 kg) Infuse 1200 mg (3 vials) over 1 hour every week for 4 weeks

Patient Weight: _____ lbs or _____ kg

In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reaction protocol.

Post Treatment Observations: The patient is observed for 1 hour following each infusion.

Comments:

PRESCRIBER INFORMATION

Prescriber Name: _____ Signature: _____
 Date: _____ NPI #: _____ Specialty: _____
 Supervising Physician: _____ (If Applicable)
 Address: _____ City: _____ State: _____ Zip: _____
 Contact Name: _____ Phone: _____ Fax: _____ Email: _____